Please use this identifier to cite or link to this item:
|Title:||Souvenaid in the management of mild cognitive impairment: an expert consensus opinion.||Austin Authors:||Cummings, Jeffrey;Passmore, Peter;McGuinness, Bernadette;Mok, Vincent;Chen, Christopher;Engelborghs, Sebastiaan;Woodward, Michael M ;Manzano, Sagrario;Garcia-Ribas, Guillermo;Cappa, Stefano;Bertolucci, Paulo;Chu, Leung-Wing||Affiliation:||Departments of Pharmacology and Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Memory Aging and Cognition Centre, National University Health System, Singapore, Singapore
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
University School for Advanced Studies IUSS, Pavia and IRCCS Istituto Centro, S. Giovanni di Dio, Brescia, Italy
Service of Cognitive and Behavioral Neurology, Department of Neurology and Neurosurgery, Federal University of São Paulo, São Paulo, Brazil
Centre for Public Health, Institute of Clinical Sciences, Queens University Belfast, Belfast, UK
Department of Medicine, The University of Hong Kong and Hong Kong Brain Memory Centre, Hong Kong Special Administrative Region, China
Therese Pei Fong Chow Research Center for Prevention of Dementia, Gerald Choa Neuroscience Centre, Lui Che Woo Institute of Innovative Medicine, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
Department of Neurology, Centre for Neurosciences, UZ Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium
Department of Brain Health, School of Integrated Health Sciences, UNLV; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
Reference Centre for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium
Neurology Department, Infanta Leonor Hospital, Madrid, Spain..
Servicio de Neurología, Hospital Universitario Ramón y Cajal, Madrid, Spain..
|Issue Date:||17-Aug-2019||metadata.dc.date:||2019-08-17||Publication information:||Alzheimer's research & therapy 2019; 11 (1): 73||Abstract:||Mild cognitive impairment (MCI) among an aging global population is a growing challenge for healthcare providers and payers. In many cases, MCI is an ominous portent for dementia. Early and accurate diagnosis of MCI provides a window of opportunity to improve the outcomes using a personalized care plan including lifestyle modifications to reduce the impact of modifiable risk factors (for example, blood pressure control and increased physical activity), cognitive training, dietary advice, and nutritional support. Souvenaid is a once-daily drink containing a mixture of precursors and cofactors (long-chain omega-3 fatty acids, uridine, choline, B vitamins, vitamin C, vitamin E, and selenium), which was developed to support the formation and function of neuronal membranes and synapses. Healthcare providers, patients, and carers require expert advice about the use of Souvenaid. An international panel of experts was convened to review the evidence and to make recommendations about the diagnosis and management of MCI, identification of candidates for Souvenaid, and use of Souvenaid in real-world practice. This article provides a summary of the expert opinions and makes recommendations for clinical practice and future research. Early diagnosis of MCI requires the use of suitable neuropsychological tests combined with a careful clinical history. A multimodal approach is recommended; dietary and nutritional interventions should be considered alongside individualized lifestyle modifications. Although single-agent nutritional supplements have failed to produce cognitive benefits for patients with MCI, a broader nutritional approach warrants consideration. Evidence from randomized controlled trials suggests that Souvenaid should be considered as an option for some patients with early Alzheimer's disease (AD), including those with MCI due to AD (prodromal AD). Early and accurate diagnosis of MCI provides a window of opportunity to improve the outcomes using a multimodal management approach including lifestyle risk factor modification and consideration of the multinutrient Souvenaid.||URI:||http://ahro.austin.org.au/austinjspui/handle/1/21632||DOI:||10.1186/s13195-019-0528-6||PubMed URL:||31421681||Type:||Journal Article||Subjects:||Cognition
Mild cognitive impairment
Prodromal Alzheimer’s disease
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 2, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.